BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)

Brodsky & Smith said it is conducting investigations and invited shareholders who own shares to contact the firm. The notice gives no company names, investigation details, or financial figures.

Analysis

This is a solicitation to discuss unspecified investigations, not evidence of a filed lawsuit, regulatory finding, or quantified financial exposure. With no companies or alleged conduct identified, there is no defensible issuer-level earnings, balance-sheet, or valuation read-through—and no basis for a trade. Any near-term impact is limited to possible noise if later coverage identifies a widely held target; the economic significance would depend on the claim, procedural stage, and any effect on a pending transaction or operating practices. Over the next 1–3 months, watch for named targets, court filings, and company disclosures. A finding that the notice remains unconnected to a filed case would further weaken the signal; a complaint affecting a material transaction or seeking consequential relief would change the assessment. The key contrarian point is that investigation notices are not equivalent to meritorious claims, but they should not be dismissed if subsequent filings establish concrete exposure.

Key Decisions for Investors

• No position on this notice alone: the targets, claims, and any relevant securities or transactions are unspecified.
• If a portfolio holding is later named, verify the court docket, alleged conduct, requested relief, class period, and company response before adjusting exposure.
• Escalate only if filings or disclosures indicate a plausible material effect on a pending deal, guidance, liquidity, or governance; otherwise treat the notice as low-signal legal noise.